Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 25;15(3):750.
doi: 10.3390/cancers15030750.

Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study

Ivan Guerra  1 , Luis Bujanda  2   3 , Miriam Mañosa  3   4 , Isabel Pérez-Martínez  5 , María José Casanova  3   6 , Luisa de la Peña  7 , Marina de Benito  8 , Montserrat Rivero  9 , Pilar Varela  10 , Lorena Bernal  3   11 , Ana Carolina Franco  12 , Yolanda Ber  13 , Marta Piqueras  14 , Carlos Tardillo  15 , Ángel Ponferrada  16 , Sonsoles Olivares  17 , Alfredo J Lucendo  3   18 , Pau Gilabert  19 , Mónica Sierra Ausín  20 , María Bellart  1 , Amaia Herrarte  2   3 , Margalida Calafat  3   4 , Ruth de Francisco  5 , Javier P Gisbert  3   6 , Jordi Guardiola  7 , Eugeni Domènech  3   4 , Fernando Bermejo  1 ; ENEIDA project of GETECCU
Affiliations

Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study

Ivan Guerra et al. Cancers (Basel). .

Abstract

An increased risk of lymphoma has been described in patients with inflammatory bowel disease (IBD). The aims of our study were to determine the clinical presentation, the previous exposure to immunosuppressive and biologic therapies, and the evolution of lymphomas in patients with IBD. IBD patients with diagnosis of lymphoma from October 2006 to June 2021 were identified from the prospectively maintained ENEIDA registry of GETECCU. We identified 52 patients (2.4 cases of lymphoma/1000 patients with IBD; 95% CI 1.8-3.1). Thirty-five were men (67%), 52% had ulcerative colitis, 60% received thiopurines, and 38% an anti-TNF drug before lymphoma diagnosis. Age at lymphoma was lower in those patients treated with thiopurines (53 ± 17 years old) and anti-TNF drugs (47 ± 17) than in those patients not treated with these drugs (63 ± 12; p < 0.05). Five cases had relapse of lymphoma (1.7 cases/100 patient-years). Nine patients (17%) died after 19 months (IQR 0-48 months). Relapse and mortality were not related with the type of IBD or lymphoma, nor with thiopurines or biologic therapies. In conclusion, most IBD patients had been treated with thiopurines and/or anti-TNF agents before lymphoma diagnosis, and these patients were younger at diagnosis of lymphoma than those not treated with these drugs. Relapse and mortality of lymphoma were not related with these therapies.

Keywords: anti-TNF; inflammatory bowel disease; lymphoma; thiopurines.

PubMed Disclaimer

Conflict of interest statement

I.G. has served as speaker of has received education funding from Takeda and Tillots. J.P.G. has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine and Vifor Pharma. E.D. has served as a speaker or has received research or education funding or advisory fees from AbbVie, Adacyte Therapeutics, Biogen, Celltrion, Galapagos, Gilead, Imidomics, Janssen, Kern Pharma, MSD, Pfizer, Roche, Samsung, Takeda, Tillots.

Figures

Figure 1
Figure 1
Survival Kaplan–Meier curve of patients with IBD after lymphoma diagnosis. IBD: inflammatory bowel disease. NHL: non-Hodgkin lymphoma. Aggressive NHL: diffuse large B-cell lymphoma, mantle cell lymphoma, plasmablastic lymphoma, and cutaneous lymphoma. Indolent NHL: follicular, marginal zone, and lymphoplasmacytic lymphoma. Five-year survival rate: 80% aggressive NHL, 84% Hodgkin lymphoma, 89% indolent NHL. Ten-year survival rate: 80% aggressive NHL, 72% Hodgkin lymphoma, 89% indolent NHL. Log-rank p > 0.05.
See this image and copyright information in PMC

References

    1. Annese V., Beaugerie L., Egan L., Biancone L., Bolling C., Brandts C., Dierickx D., Dummer R., Fiorino G., Gornet J.M., et al. European Evidence-Based Consensus: Inflammatory Bowel Disease and Malignancies. J. Crohn’s Colitis. 2015;9:945–965. doi: 10.1093/ecco-jcc/jjv141. - DOI - PubMed
    1. Lo B., Zhao M., Vind I., Burisch J. The Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies. Clin. Gastroenterol. Hepatol. 2021;19:1117–1138.e19. doi: 10.1016/j.cgh.2020.08.015. - DOI - PubMed
    1. Lemaitre M., Kirchgesner J., Rudnichi A., Carrat F., Zureik M., Carbonnel F., Dray-Spira R. Association between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients with Inflammatory Bowel Disease. JAMA. 2017;318:1679–1686. doi: 10.1001/jama.2017.16071. - DOI - PMC - PubMed
    1. Kotlyar D.S., Lewis J.D., Beaugerie L., Tierney A., Brensinger C.M., Gisbert J.P., Loftus E.V., Peyrin-Biroulet L., Blonski W.C., Van Domselaar M., et al. Risk of Lymphoma in Patients with Inflammatory Bowel Disease Treated with Azathioprine and 6-Mercaptopurine: A Meta-Analysis. Clin. Gastroenterol. Hepatol. 2015;13:847–858.e4. doi: 10.1016/j.cgh.2014.05.015. - DOI - PubMed
    1. Zabana Y., Panés J., Nos P., Gomollón F., Esteve M., García-Sánchez V., Gisbert J.P., Barreiro-de-Acosta M., Domènech E. The ENEIDA Registry (Nationwide Study on Genetic and Environmental Determinants of Inflammatory Bowel Disease) by GETECCU: Design, Monitoring and Functions. Gastroenterol. Hepatol. 2020;43:551–558. doi: 10.1016/j.gastrohep.2020.05.007. - DOI - PubMed